Compare Stocks: HYFT, FULC, MGNX, and JMAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$3.77 -0.8%	$3.81	$2.83 ▼ $15.74	$289.93M	3.05	1.62 million shs	1.25 million shs
HYFT MindWalk	$1.32 -2.9%	$1.53	$0.99 ▼ $3.25	$63.53M	0.84	257,781 shs	107,265 shs
JMAC Maxpro Capital Acquisition	$17.58 +1.9%	$17.35	$7.50 ▼ $19.22	$236.00M	0.01	74,040 shs	4,075 shs
MGNX MacroGenics	$3.90	$4.24	$1.29 ▼ $5.08	$247.90M	1.2	803,111 shs	263,569 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-0.79%	+4.14%	+1.34%	-45.20%	-45.20%
HYFT MindWalk	-2.94%	-1.12%	-19.51%	+10.00%	+131,999,900.00%
JMAC Maxpro Capital Acquisition	+1.91%	-3.54%	-10.15%	+15.32%	+199.40%
MGNX MacroGenics	0.00%	+6.27%	-14.66%	+32.65%	+130.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FULC Fulcrum Therapeutics	$3.77 -0.8%	$3.81	$2.83 ▼ $15.74	$289.93M	3.05	1.62 million shs	1.25 million shs
HYFT MindWalk	$1.32 -2.9%	$1.53	$0.99 ▼ $3.25	$63.53M	0.84	257,781 shs	107,265 shs
JMAC Maxpro Capital Acquisition	$17.58 +1.9%	$17.35	$7.50 ▼ $19.22	$236.00M	0.01	74,040 shs	4,075 shs
MGNX MacroGenics	$3.90	$4.24	$1.29 ▼ $5.08	$247.90M	1.2	803,111 shs	263,569 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FULC Fulcrum Therapeutics	-0.79%	+4.14%	+1.34%	-45.20%	-45.20%
HYFT MindWalk	-2.94%	-1.12%	-19.51%	+10.00%	+131,999,900.00%
JMAC Maxpro Capital Acquisition	+1.91%	-3.54%	-10.15%	+15.32%	+199.40%
MGNX MacroGenics	0.00%	+6.27%	-14.66%	+32.65%	+130.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FULC Fulcrum Therapeutics	1.75	Reduce	$8.20	117.51% Upside
HYFT MindWalk	2.40	Hold	$5.00	278.79% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.29	Hold	$5.50	41.03% Upside

Current Analyst Ratings Breakdown

Latest HYFT, FULC, MGNX, and JMAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2026	HYFT MindWalk	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	HYFT MindWalk	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	FULC Fulcrum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	HYFT MindWalk	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/3/2026	FULC Fulcrum Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight
6/2/2026	FULC Fulcrum Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Underperform ➝ Underweight
6/2/2026	FULC Fulcrum Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
6/2/2026	FULC Fulcrum Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$4.00
6/2/2026	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.00
6/2/2026	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/2/2026	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$4.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FULC Fulcrum Therapeutics	$80M	3.60	N/A	N/A	$4.07 per share	0.93
HYFT MindWalk	$11.24M	5.49	N/A	N/A	$0.18 per share	7.33
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	$149.50M	1.66	N/A	N/A	$0.88 per share	4.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FULC Fulcrum Therapeutics	-$74.88M	-$1.15	N/A	N/A	N/A	N/A	-25.38%	-24.15%	N/A
HYFT MindWalk	-$10.11M	-$0.22	N/A	N/A	N/A	-89.65%	-92.61%	-54.15%	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	-$74.62M	-$1.10	N/A	N/A	N/A	-44.79%	-147.80%	-28.40%	8/13/2026 (Estimated)

Latest HYFT, FULC, MGNX, and JMAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	N/A	N/A	N/A	$59.14 million	N/A
7/30/2026	Q2 2026	FULC Fulcrum Therapeutics	-$0.2433	-$0.34	-$0.0967	-$0.34	N/A	N/A
7/22/2026	Q4 2026	HYFT MindWalk	-$0.05	-$0.06	-$0.01	-$0.06	N/A	$3.03 million
5/13/2026	Q1 2026	MGNX MacroGenics	-$0.57	-$0.58	-$0.01	-$0.58	$15.24 million	$20.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
HYFT MindWalk	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FULC Fulcrum Therapeutics	N/A	31.35	31.35
HYFT MindWalk	0.26	2.80	2.72
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
MGNX MacroGenics	N/A	1.90	1.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FULC Fulcrum Therapeutics	89.83%
HYFT MindWalk	6.70%
JMAC Maxpro Capital Acquisition	73.18%
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
FULC Fulcrum Therapeutics	7.30%
HYFT MindWalk	6.83%
JMAC Maxpro Capital Acquisition	19.27%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FULC Fulcrum Therapeutics	100	76.30 million	70.73 million	Optionable
HYFT MindWalk	80	46.71 million	43.52 million	N/A
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
MGNX MacroGenics	430	63.56 million	54.92 million	Optionable

HYFT, FULC, MGNX, and JMAC Headlines

Recent News About These Companies

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Brokerages

August 3 at 4:15 AM | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages

August 3 at 4:13 AM | marketbeat.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

MacroGenics slips after early-stage trial data for lead asset

July 24, 2026 | seekingalpha.com

MacroGenics, Inc.: MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 24, 2026 | finanznachrichten.de

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

July 23, 2026 | tmcnet.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

July 9, 2026 | marketbeat.com

MacroGenics announces upcoming board change with director resignation

July 8, 2026 | tipranks.com

Bora Pharmaceuticals closes 122 million buy of MacroGenics Rockville manufacturing site

July 4, 2026 | msn.com

Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Manufacturing Operations

July 2, 2026 | usatoday.com

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?

July 2, 2026 | zacks.com

MacroGenics Completes Sale of GMP Drug Substance Manufacturing Operations to Bora Pharmaceuticals

July 2, 2026 | quiverquant.comQ

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

July 2, 2026 | globenewswire.com

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

June 22, 2026 | globenewswire.com

How The MacroGenics (MGNX) Story Is Shifting With ADC Pipeline Bets And 2026 Data Risks

June 7, 2026 | finance.yahoo.com

How The MacroGenics (MGNX) Story Is Shifting With ADC Hopes And Execution Risks

May 22, 2026 | finance.yahoo.com

MacroGenics Shareholders Back Board, Auditors and Equity Plan

May 20, 2026 | tipranks.com

Macrogenics Inc.

May 16, 2026 | marketwatch.com

MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are Pretty Bullish On The Stock After Recent Results

May 15, 2026 | finance.yahoo.com

MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum

May 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT, FULC, MGNX, and JMAC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

$3.77 -0.03 (-0.79%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.77 0.00 (0.00%)

As of 08/5/2026 07:38 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

MindWalk NASDAQ:HYFT

$1.32 -0.04 (-2.94%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$1.33 +0.01 (+0.76%)

As of 08/5/2026 07:34 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Maxpro Capital Acquisition NASDAQ:JMAC

$17.58 +0.33 (+1.91%)

As of 08/4/2026

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

MacroGenics NASDAQ:MGNX

$3.90 0.00 (0.00%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$4.16 +0.26 (+6.67%)

As of 08/5/2026 07:34 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HYFT, FULC, MGNX, and JMAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HYFT, FULC, MGNX, and JMAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HYFT, FULC, MGNX, and JMAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT, FULC, MGNX, and JMAC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

MindWalk NASDAQ:HYFT

Maxpro Capital Acquisition NASDAQ:JMAC

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HYFT, FULC, MGNX, and JMAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HYFT, FULC, MGNX, and JMAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HYFT, FULC, MGNX, and JMAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT, FULC, MGNX, and JMAC Company Descriptions

Fulcrum Therapeutics NASDAQ:FULC

MindWalk NASDAQ:HYFT

Maxpro Capital Acquisition NASDAQ:JMAC

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools